Here are seven observations:
1. For the fourth quarter of 2017, SeaSpine will likely see revenue between $34.2 million and $34.4 million, a 6 percent increase from the fourth quarter of 2016.
2. U.S. fourth quarter revenue will likely be $31.5 million, reflecting a 6 percent boost from the same period the year prior.
3. The U.S. orthobiologics segment will see revenues of $16.9 million, a 12 percent jump from the fourth quarter of 2016.
4. SeaSpine reports its U.S. spinal implants revenue will likely stay at $14.6 million.
5. The company’s FY 2017 revenue will fall between $132 million and $132.2 million, a 2.5 percent increase from FY 2016.
6. As of Dec. 31, 2017, SeaSpine had cash and cash equivalents of $10.8 million.
7. For 2018, SeaSpine anticipates revenue between $135 million and $139 million.
More articles on devices:
Medtronic, DePuy Synthes & more: 8 device company mergers, acquisitions & agreements
DJO Global reports patient information breach at Las Vegas hospital: 5 things to know
NuVasive’s US procedure volumes stay slow in 2017, international revenue up: 5 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
